Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
GO:004521620 | Esophagus | ESCC | cell-cell junction organization | 114/8552 | 200/18723 | 8.04e-04 | 4.16e-03 | 114 |
GO:0007030 | Liver | NAFLD | Golgi organization | 36/1882 | 157/18723 | 1.76e-06 | 7.68e-05 | 36 |
GO:00452167 | Liver | NAFLD | cell-cell junction organization | 32/1882 | 200/18723 | 5.53e-03 | 4.23e-02 | 32 |
GO:00070301 | Liver | Cirrhotic | Golgi organization | 68/4634 | 157/18723 | 2.57e-07 | 6.41e-06 | 68 |
GO:004521612 | Liver | Cirrhotic | cell-cell junction organization | 70/4634 | 200/18723 | 7.23e-04 | 5.36e-03 | 70 |
GO:00343324 | Liver | Cirrhotic | adherens junction organization | 20/4634 | 49/18723 | 9.60e-03 | 4.35e-02 | 20 |
GO:00070302 | Liver | HCC | Golgi organization | 99/7958 | 157/18723 | 1.54e-07 | 2.85e-06 | 99 |
GO:004521622 | Liver | HCC | cell-cell junction organization | 107/7958 | 200/18723 | 1.06e-03 | 6.11e-03 | 107 |
GO:003433211 | Liver | HCC | adherens junction organization | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
GO:00452168 | Lung | IAC | cell-cell junction organization | 43/2061 | 200/18723 | 1.21e-05 | 3.64e-04 | 43 |
GO:00439545 | Lung | IAC | cellular component maintenance | 17/2061 | 61/18723 | 2.24e-04 | 3.89e-03 | 17 |
GO:00070303 | Lung | IAC | Golgi organization | 32/2061 | 157/18723 | 4.13e-04 | 6.22e-03 | 32 |
GO:00343325 | Lung | IAC | adherens junction organization | 13/2061 | 49/18723 | 1.95e-03 | 1.97e-02 | 13 |
GO:00343315 | Lung | IAC | cell junction maintenance | 10/2061 | 35/18723 | 3.52e-03 | 2.98e-02 | 10 |
GO:004521613 | Lung | AIS | cell-cell junction organization | 41/1849 | 200/18723 | 4.66e-06 | 2.31e-04 | 41 |
GO:000703011 | Lung | AIS | Golgi organization | 30/1849 | 157/18723 | 3.09e-04 | 5.63e-03 | 30 |
GO:004395411 | Lung | AIS | cellular component maintenance | 15/1849 | 61/18723 | 6.88e-04 | 1.02e-02 | 15 |
GO:003433112 | Lung | AIS | cell junction maintenance | 9/1849 | 35/18723 | 5.76e-03 | 4.81e-02 | 9 |
GO:004521623 | Lung | MIAC | cell-cell junction organization | 26/967 | 200/18723 | 1.38e-05 | 9.86e-04 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIFC3 | SNV | Missense_Mutation | rs781911915 | c.719G>A | p.Arg240Gln | p.R240Q | Q9BVG8 | protein_coding | tolerated(0.58) | benign(0.088) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
KIFC3 | SNV | Missense_Mutation | novel | c.644A>G | p.Glu215Gly | p.E215G | Q9BVG8 | protein_coding | deleterious(0.03) | benign(0.366) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIFC3 | SNV | Missense_Mutation | | c.1267N>G | p.Arg423Gly | p.R423G | Q9BVG8 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIFC3 | SNV | Missense_Mutation | rs782647619 | c.1423C>T | p.Arg475Trp | p.R475W | Q9BVG8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIFC3 | SNV | Missense_Mutation | rs201690727 | c.2033G>A | p.Arg678Gln | p.R678Q | Q9BVG8 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
KIFC3 | SNV | Missense_Mutation | novel | c.1128N>A | p.Met376Ile | p.M376I | Q9BVG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.495) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
KIFC3 | SNV | Missense_Mutation | novel | c.1933N>G | p.Asn645Asp | p.N645D | Q9BVG8 | protein_coding | deleterious(0.01) | benign(0.386) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIFC3 | SNV | Missense_Mutation | novel | c.304N>A | p.Ala102Thr | p.A102T | Q9BVG8 | protein_coding | tolerated_low_confidence(0.5) | benign(0) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIFC3 | SNV | Missense_Mutation | rs782066289 | c.2261N>T | p.Ser754Leu | p.S754L | Q9BVG8 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIFC3 | SNV | Missense_Mutation | rs782356063 | c.1417N>T | p.Arg473Cys | p.R473C | Q9BVG8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |